Supportive Care

A significant portion of patients with lower-risk myelodysplastic syndromes achieved red-blood transfusion independence with luspatercept with no new safety signals.

The FDA has approved sodium thiosulfate to protect the hearing of pediatric patients who are at least 1 year old and are receiving cisplatin-based treatments.

Mary Anderson, BSN, RN, OCN; and Christina Bach, MBE, MSW, LCSW, OSW-C, FAOSW, discuss approaches to help patients navigate financial toxicity and insurance coverage in the age of oral anticancer drugs.

Intense-modulated therapy was associated with less patient-reported toxicities than conventional radiotherapy and demonstrated a comparable efficacy profile.

Julie Malo, CCRP, a research nurse with the University of Montreal, discusses a nurse-directed initiative examining how the gut microbiome affects immune checkpoint blockade responses in patients with non–small cell lung cancer.

Karen Hande, PhD(c), DNP, ANP-BC, CNE, FAANP, ANEF, explains the difference between some of the popular cannabinoid products that patients with cancer may be taking.

In this episode of “The Vitals,” Christine Miaskowski, PhD, RN, discusses research showcasing that adult patients receiving either a platinum-based chemotherapy, taxane alone, or a combined regimen of platinum- and taxane-based treatment may be at risk of hearing loss.

Innovative strategies are needed to ensure that adolescents and young adults with cancer who prefer to die at home are able to make that choice.

Donna Catamero, ANP-BC, OCN, CCRC, presented on her experience in expanding satellite clinical trial operations during the International Myeloma Society’s 6th Annual Nursing Symposium.

Findings from the SHAWL study found that sexual dysfunction rates are high among women with lung cancer.

There is no one-size-fits-all approach to establishing patient-reported outcome measures, according to Hayley Beer, RN.

An observational study found no association between single-agent vaginal estrogen therapy or menopausal hormone therapy and increased risk of recurrence or mortality in patients with breast cancer.

Investigators at Dana-Farber Cancer Institute are developing a virtual frailty assessment, which combines both patient-reported outcomes and standardized performance measures.

Ibrutinib is now an FDA-approved treatment for patients aged 1 year or older who have chronic graft-versus-host-disease. Prescription warnings include bleeding and cardiac problems, infections, high blood pressure, a decrease in blood cell count, and tumor lysis syndrome.

Advanced practice providers play a critical role in increasing palliative care referrals.

Entering the words nutrition and cancer into Google returns as many as 718 million hits. With an overabundance of opinions, it can be challenging to separate fact from fiction.

Hearing loss for cancer survivors is largely underreported, but once identified, is easily treatable, according to Christine Miaskowski, PhD, RN.

Betibeglogene autotemcel is the first FDA-approved cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who need routine blood tranfusions.

An ASCO expert panel conducted a comprehensive literature assessment to determine how diet, weight, and exercise play a role in defining patient outcomes.

Sherry Adkins, MSN, ANP-C, discusses some key considerations in ensuring quality patient care after they have completed CAR T-cell therapy at a specialized center.

The Florida Senate recently passed the No Patient Left Alone Act SB 988, which will allow visitors back into the hospital, regardless of their COVID-19 vaccination, so that no patient will wake from surgery or find themselves in hospice, without a family member by their side.

Gabriella Magarelli, MSN, ACNP-BC, AOCNP, reflects on lessons learned caring for patients with cancer and COVID-19.

Lidia Schapira, MD, FASCO, discusses the importance of rigorous baseline measurement in improving the assessment and management of distressful cancer symptoms.

Pediatric oncology nurses and social workers routinely collaborate not only in the biopsychosocial assessment of families’ psychosocial needs and distress, but in developing interventions that can improve a patient’s and family’s quality of life while in pediatric cancer treatment and in survivorship.

Gretchen McNally PhD, ANP-BC, AOCN, spotlights the value that naloxone training for oncology nurses and providers could have for patients who are at a high-risk of overdose.

In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.

Gretchen McNally PhD, ANP-BC, AOCNP, discusses the potential impact advanced practice providers and nurses could have in the opioid pandemic if the correct educational opportunities were available.